Theralase Technologies Inc (TLTFF)

[123414]

Slowed burn rate and milestones completed.
Theralase will have a few monthes of slower burn rate as the Phase 2 trial gets kicked off.

Each day that passes will bring us closer to an annoucement reguarding company plans to meet with Health Canada and FDA, to discuss and finalize the design of a Health Canada and FDA pivotal Phase II NMIBC clinical study, with a primary endpoint of efficacy.

How much value will the market give credit to Theralase for the annoucement? It will be another milestone met like the completed Phase 1 trial and a marker of stong progress made by the company.